Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Rachel B Britt"'
Autor:
Anna M Hu, Marc J Pepin, Mohamed G Hashem, Rachel B Britt, Sara R Britnell, William E Bryan, Jamie N Brown
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 79(8)
Purpose To describe the development of a pilot specialty medication clinical dashboard targeting tumor necrosis factor (TNF)-α inhibitor therapy. Summary This was a quality improvement project conducted between August 2019 and April 2020. The dashbo
Publikováno v:
Annals of Pharmacotherapy. 53:581-587
Background: Substance use disorders (SUDs) are commonly encountered in patients with chronic hepatitis C virus (HCV) infection. It is important to consider the impact of SUDs on HCV treatment. Objective: To compare the rate of clinical cure (sustaine
Publikováno v:
International journal of geriatric psychiatryREFERENCES. 36(9)
Objectives Geriatric depression is common and is often associated with coexisting medical illnesses, cognitive dysfunction, or both. Treatment with pharmacotherapy is usually required, and many patients may not respond to initial therapy. Thus, there
Autor:
Ashley H. McKnight, Rachel B. Britt, Mohamed G. Hashem, Lawrence P. Park, Mary L. Townsend, Susanna Naggie
Publikováno v:
The Annals of pharmacotherapy. 54(11)
Background: Response-guided hepatitis C therapy was standard with interferon-based regimens but is not used for direct-acting antivirals (DAAs). Week 4 viral kinetics may predict sustained virological response (SVR) with DAAs, but it is unclear wheth
Autor:
William E. Bryan, Tzu-Hao Lee, Austin Chan, Mary L. Townsend, Cynthia A. Moylan, Susanna Naggie, Steve S. Choi, Mohamed G. Hashem, Lawrence P. Park, Rachel B. Britt
Publikováno v:
J Viral Hepat
Background Previous studies have reported an association of proton pump inhibitor (PPI) use and decreased sustained viral response rate (SVR) in patients taking ledipasvir/sofosbuvir (LDV/SOF). The relationship between PPI usage and SVR is less clear
Publikováno v:
Annals of Pharmacotherapy. 52:763-768
Background: Many direct-acting antivirals (DAAs) have drug-drug interactions (DDIs) with the potential to affect efficacy and safety. Objective: To describe the incidence and severity of DDIs with DAAs identified by the hepatitis C virus (HCV) clinic
Autor:
Mohamed G. Hashem, Jonathan C. Hale, Jamie N. Brown, Sherin Jacob, Rachel B. Britt, William E. Bryan
Publikováno v:
Journal of managed carespecialty pharmacy. 25(3)
The establishment of a formulary management system ensures that health care professionals work together in an integrated patient care process to promote clinically sound, safe, and cost-effective medication therapy. Pharmacists have a foundational ro
Publikováno v:
Federal practitioner : for the health care professionals of the VA, DoD, and PHS. 36(1)
NAFLD improves with 7% or greater weight loss.
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 36:1173-1179
tudy Objective To describe international normalized ratio (INR) trends and warfarin dosage adjustments required for four veterans who were receiving warfarin therapy and started treatment for hepatitis C virus (HCV) with ledipasvir/sofosbuvir with or
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 22:1056-1061
Several cost analysis studies have been conducted looking at clinical and economic outcomes associated with clinical pharmacist services in a variety of health care settings. However, there is a paucity of data regarding the economic impact of clinic